FDA Brief

Warning letters Drugs

FDA warning letter to

Purecraft LLC

High riskIssued Jan 10, 2023Posted Jan 11, 2023Center for Drug Evaluation and Research | CDER

FDA and FTC warn Purecraft LLC over CBD products marketed with unapproved COVID-19 prevention and treatment claims.

What happened

FDA reviewed purecraftcbd.com on December 14, 2022, and FTC reviewed it on January 6, 2023; FDA also reviewed the company's Facebook and Instagram pages. The website offered CBD products and included blog and social media claims that CBD could prevent, treat, or reduce COVID-19 symptoms and affect SARS-CoV-2. FDA called the products unapproved new drugs and misbranded drugs, and FTC said the COVID-19 disease claims lacked competent and reliable scientific evidence.

What FDA found

  1. The CBD products are unapproved new drugs because they are sold with COVID-19 claims without FDA approval.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. The products are misbranded, meaning their labeling is not compliant, under section 502 of the FD&C Act.

    FD&C Act section 502, 21 U.S.C. § 352
  3. Introducing or delivering these products into interstate commerce is prohibited.

    FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. The company advertised that its CBD products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. Deceptive claims about COVID-19 treatment, cure, prevention, or mitigation can bring civil penalties under the COVID-19 Consumer Protection Act.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA and FTC ask Purecraft LLC to immediately stop selling and claiming that these CBD products can mitigate, prevent, treat, diagnose, or cure COVID-19. Within 48 hours, the company must email FDA with the steps taken and email FTC certifying that it has ceased the unsubstantiated claims.

Who should pay attention

  • CBD brands making health claims
  • retailers and online marketplaces selling CBD
  • advertising and marketing teams for supplement or drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk